Oct 04, 2022

To examine the safety and efficacy of niraparib+bevacizumab as first-line maintenance therapy for patients with newly diagnosed advanced ovarian cancer. This multicenter, phase II, single-arm, open-la...

Oct 04, 2022

Treatment options for advanced vulvar cancer are limited. Researchers evaluated pembrolizumab monotherapy in patients with advanced vulvar squamous cell carcinoma (SCC) enrolled in phase 2 multicohort...

Oct 03, 2022

A multidisciplinary agreement was used to determine whether or not patients diagnosed with advanced epithelial ovarian cancer (AEOC) between October 2018 and October 2020 should receive primary chemot...

Oct 03, 2022

The goal of this study was to compare the efficacy of an ultrasound-guided block (US-Tap) and laparoscopically-guided transversus abdominis plane block (Lap-Tap) with liposomal bupivacaine in the trea...

Oct 03, 2022

For patients with BRCA1/BRCA2-mutated (BRCAm), platinum-sensitive relapsed ovarian cancer (PSROC), and 2 prior lines of platinum-based chemotherapy, the SOLO3 phase III trial found that treatment with...

Oct 03, 2022

As shown by the Laparoscopic Approach to Cervical Cancer (LACC) trial, early-stage cervical carcinoma patients who undergo a minimally invasive (MIS) radical hysterectomy have poorer oncologic outcome...

Oct 03, 2022

If a patient with advanced epithelial ovarian cancer (EOC) lives without disease progression for 10 years after diagnosis, they are considered to be cured. Researchers describe the percentage of patie...

Oct 03, 2022

Researchers claim that they conducted a Phase I trial to assess the efficacy and safety of paclitaxel, sapanisertib, and serabelisib. This was an open-label cohort trial comparing sapanisertib (TAK-22...

Oct 03, 2022

According to researchers, a patient's understanding of surgery is often limited in the context of sophisticated oncologic operations. Supplemental materials can help patients learn more about their su...

Oct 03, 2022

Recurrent ovarian cancer (rOC) responds well to anti-angiogenic therapy with bevacizumab in combination with chemotherapy; however, information on tyrosine kinase inhibitors following progression on m...

Oct 03, 2022

The purpose of researchers was to determine if gynecologic cancer patients who undergo surgery have a higher risk of postoperative problems, readmissions, or discharge locations other than a home usin...

Oct 03, 2022

To investigate the relative contributions of individual insurance status and hospital payer mix (safety net status) to quality of care and survival for patients with cervical cancer. Researchers used ...

Sep 15, 2022

Patients with recurrent cervical or endometrial cancer were included in this study to evaluate the safety and efficacy of combination bevacizumab rucaparib treatment. About 33 individuals were enrolle...

Sep 15, 2022

The goal of this study was to determine if the effectiveness of first-line maintenance therapy with niraparib differs among patients with newly diagnosed advanced ovarian cancer based on the timing of...

Sep 15, 2022

The purpose of this study is to determine whether or not substantial postoperative problems have a negative effect on survival for patients with advanced ovarian cancer who have undergone cytoreductiv...

Sep 15, 2022

The aggressive endometrial cancer subtype known as uterine serous carcinoma (USC) has a dismal survival rate. In advanced/recurrent HER2/neu-positive USC, trastuzumab is a known target because approxi...

Sep 15, 2022

Historically, Lynch syndrome genes or PTEN have been linked to hereditary uterine cancer (UC); however, there is mounting evidence that other genes have a role and may offer novel clinical therapy opt...

Sep 15, 2022

A substantial death rate is linked to high-grade serous ovarian cancer (HGSOC), the most frequent subtype of ovarian cancer. Surgical success or failure is a major indicator of long-term health. Prese...

Sep 15, 2022

It has recently come to light that the epigenetic alteration of adenosine to inosine (A-to-I) RNA editing is a critical carcinogenic process in human malignancies. Its clinical importance and function...

Sep 15, 2022

It is still unclear what the best adjuvant treatment for uterine leiomyosarcoma (uLMS) is. Researchers assessed the rate at which stage II and stage III uLMS patients received adjuvant chemotherapy an...